Carl Wettinck

Carl advises on all aspects of Belgian, EU, and international antitrust law, including multi-jurisdictional merger control filings, cartel investigations, leniency issues, abuse of dominance cases, and compliance matters. His practice places particular focus on assisting Belgian and international clients in the telecommunications, media and technology sectors.

Image
Carl Wettinck Stibbe

Carl Wettinck

Senior Associate Brussels

Carl advises on all aspects of Belgian, EU, and international antitrust law, including multi-jurisdictional merger control filings, cartel investigations, leniency issues, abuse of dominance cases, and compliance matters. His practice places particular focus on assisting Belgian and international clients in the telecommunications, media and technology sectors.

Carl Wettinck

Senior Associate Brussels

Carl advises clients on antitrust matters, drawing on his extensive public sector experience as a former prosecutor with the Belgian Competition Authority. Having been involved in several high-profile merger cases and investigations, he brings deep expertise in enforcement proceedings at both Belgian and European levels.

Carl obtained a Master’s degree in Law from Ghent University in 2003. Before joining Stibbe’s Brussels office, he practiced as a competition lawyer at the Brussels office of an international law firm for nearly four years, following six years as a competition prosecutor at the Belgian Competition Authority.

Languages: Dutch, English, French
Admitted to the Brussels Bar: 2021
xxx
Matter
NL Law

Stibbe adviseert Jumbo-familie Van Eerd bij overname HEMA

Stibbe heeft Mississippi Ventures, het investeringsvehikel van de familie Van Eerd (eigenaar van supermarktketen Jumbo), geadviseerd bij de overname van de overige 50 procent van de aandelen in HEMA.

Continue reading
xxx
Matter
NL Law

Stibbe advises Jumbo family Van Eerd on acquisition of Hema

Stibbe advised Mississippi Ventures, the investment vehicle of the Van Eerd family (owners of supermarket chain Jumbo), on the acquisition of the remaining 50 per cent of the shares in HEMA.

Continue reading